Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib in life-threatening rare malignant diseases
NCT00154388Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2001
- Primary completion
- Jan 2007
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of imatinib in malignant neoplasm, sponsored by Novartis. Primary endpoints: Effect of Imatinib mesylate treatment and Contribution of specific protein tyrosine kinases. Started Feb 2001; status: completed.
02
Drugs
03
Conditions
malignant neoplasm
Beyond the preview
Go deeper on NCT00154388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00154388.